Accredited Symposia

Each symposium has been approved for 1.5 CME credits


Wednesday, June 21, 2017

17:15-18:45
Afternoon Symposium

Co-developed by Valeant Canada and the CDA

Chair: Charles Lynde

Biologic Treatment Options for Psoriasis in 2017: Redefining Treatment Success

Great strives have been made in recent years in the treatment of psoriasis. Once thought to be unachievable, PASI 100 is now within the clinicians’ reach. However, the question remains: what does PASI 100 actually mean for the patient and the clinician?  In this symposium, we will review new biologic treatment options and the clinical benefits of complete skin clearance to patients.  As well, we will explore the patient’s perspective through a series of patient cases, and how efficacy should or should not affect treatment decisions.

Agenda

17:15-17:25 Introduction, objectives, and unmet needs in psoriasis Charles Lynde
17:25-17:45 Bridging the treatment gap with new biologic treatment options for psoriasis and achieving complete skin clearance Melinda Gooderham
17:45-18:05 Co-morbidities associated with psoriasis and the safety of biologic treatments Kim Papp
18:05-18:20 Clinical cases demonstrating treatment options for patients with inadequate treatment response to biologic therapy Ian Landells
18:20-18:30 Interactive panel discussion/questions and answers Facilitated by Charles Lynde
18:30-18:40 Post Symposium Survey Facilitated by Charles Lynde
18:40-18:45 Conclusion and closing remarks Charles Lynde

 

Learning Objectives

  1. Explore the patient’s perspective on psoriasis treatments and the impact of complete skin clearance on patient satisfaction and quality of life
  2. Review new biologic treatment options for treating psoriasis, their efficacy, safety, and the clinical benefits to the patient
  3. Gain a deeper understanding of the co-morbidities associated with psoriasis
  4. Consider treatment options for patients not satisfied with the level of skin clearance achieved with current biologic therapy

 

Thursday, June 22, 2017

08:30-10:00
Breakfast Symposium

Co-developed by Eli Lilly and the CDA

The Target Remains Clear: “New Updates on IL-17 Inhibition in Psoriasis”

This symposium will expand upon last year’s award-winning CDA symposium, The Target is Clear, by providing participants with the most up-to-date efficacy and safety data on the use of IL-17 inhibitors for the treatment of psoriasis. Participants will also have the opportunity to reflect on how this novel therapeutic class may be changing the treatment expectations of both patients and physicians. Using a highly-interactive format, various topics relevant to clinical practice will be addressed including: long-term safety and efficacy, drug survival and longevity of response; challenges to the successful treatment of psoriasis with the newer biologics; meeting patient needs and improving quality of life; and optimizing outcomes in difficult-to-treat cases.

Learning Objectives

After attending this session, participants will be able to:

  • Assess their knowledge of the core efficacy data on IL-17 inhibitors and quantify the opportunity for higher levels of clearance;
  • Interpret the most up-to-date clinical efficacy data emerging from recent congresses and publications (e.g. speed of onset, long-term data and longevity of response, difficult to treat areas, PsA);
  • Evaluate the current cumulative safety data for IL-17 inhibitors (e.g. IBD, neuropsychiatric effects);
  • Relate quality of life measures to patients’ perspectives of disease and treatment success.

 

18:15-19:45
Dinner Symposium (New for 2017)

Co-developed by Novartis Pharmaceuticals Canada and the CDA

Chair: Marc Bourcier

Differential diagnosis using a multi-disciplinary approach in psoriasis, psoriatic arthritis, chronic idiopathic urticaria and auto-inflammatory disease

Background

In 2067 all patients walking in to a doctor’s office might have a barcode which will offer the right diagnosis, with the right therapeutic approach and in turn offer on the spot the right treatment to describe the best chance of success.

However, in 2017 there is still a need for a differential diagnosis.  Lengthy diagnosis and delayed treatment provides for more complexity for overall patient health.  This symposium will address how a multi-disciplinary team would work together to reduce the complexity for patient treatment and offer more efficient management of overall patient care.

Description

The symposium will feature a panel of multi-disciplinary specialists who will provide insights on the patient journey, and management & treatment of psoriasis (PsO), psoriatic arthritis (PsA), chronic idiopathic urticaria (CIU), and auto inflammatory disease (AI). The panel will focus on how a multi-disciplinary team can work together to improve patient care and accelerate the patient journey.

Agenda

18:15-18:25 Introduction
Welcome and introductions
Patient cases
Marc Bourcier
18:25-18:50 Case #1 – Psoriatic Arthritis
Patient Journey
Multi-disciplinary management discussion
Treatment options
2 questions
Neil Shear & Sibel Aydin
18:50-19:15 Case #2 – Chronic Idiopathic Urticaria
Patient Journey
Multi-disciplinary management discussion
Treatment options
2 questions
Neil Shear & Hugo Chapdelaine
19:15-19:40 Case #3 – Auto Inflammatory Disease
Patient Journey
Multi-disciplinary management discussion
Treatment options
2 questions
Hugo Chapdelaine
19:40-19:45 Final Q&A

 

Learning Objectives

By the end of the symposium, the audience will be able to:

  • Understand and describe the lengthy journey of the complex PsO, PsA, CIU and AI patients
  • Discuss how a multi-disciplinary management approach can lead towards efficiently accelerating patient care
  • Assess therapies for the treatment of PsO, PsA, CIU and AI, based on clinically relevant data

 

Friday, June 23, 2017

08:30-10:00
Breakfast Symposium

Co-developed by Pierre Fabre Dermo-Cosmétique and the CDA

Treating Infantile Hemangiomas in 2017: Who? When? And How?

Speakers

  • Julie Powell
  • Francine Blei

In recent years, the approach to infantile hemangioma (IH) treatment has changed dramatically. There is better understanding of IH growth, better identification of high-risk IH and better treatment options. Current management aims not only to reverse complications but to prevent them, by early recognition and timely initiation of treatment.  As well, with the availability of safer therapeutic options, active intervention should be considered not only for life or function-threatening IH but also for prevention of long-term sequelae impacting quality of life.

Learning Objectives

At the end of the session, participants will:

  1. Understand infantile hemangiomas – clinical impact and QOL.
  2. Be able to diagnose IH: when and who to treat.
  3. Understand current IH treatment options.

 

12:40-14:10
Luncheon Symposium

Co-developed by Galderma and the CDA

Chair: Jerry Tan

An Expert Roundtable Discussion: Update in New Developments in Severe Acne

Severe inflammatory acne affects many Canadian adolescents and adults with limited treatment options. Isotretinoin has been the standard of treatment for severe acne for more than 30 years, however due to its known teratogenicity, pregnancy prevention programs and monitoring are required for women of childbearing age.  This expert roundtable discussion will assess and critique two current articles focused on severe acne, including 1) the efficacy and safety of a new treatment for severe inflammatory acne vulgaris, adapalene 0.3%-benzoyl peroxide 2.5% gel, and 2) the evaluation of Canadian pregnancy prevention programs with the use of Isotretinoin.  Participants will be provided with pre-event reading materials and are invited to submit questions to be discussed during the event.  This symposium will include audience interaction and discussions on key issues facing Canadian Dermatologists.

Speakers

  • Jerry Tan, MD, FRCPC, Adjunct Associate Professor, Schulich School of Medicine, Western University; Department of Psychology, University of Windsor, Windsor, ON
  • Anick Bérard, PhD, Assistant Professor, Albert Einstein College of Medicine, New York, New York; Professor, Faculty of Pharmacy, University of Montreal, CHU Sainte-Justine Research Center, Montreal, QC
  • Melinda Gooderham, MD, MSc, FRCPC, Medical Director, SKiN Centre for Dermatology; Assistant Professor, Queen’s University; Consultant Physician, Peterborough Regional Health Centre (PRHC), Peterborough, ON

Agenda

12:40-12:45 Welcome and Introductions
12:45-13:10 Article 1
Customized Single-agent Therapy Management of Severe Inflammatory Acne: A Randomized, Double-blind, Parallel-group, Controlled Study of a New Treatment – Adapalene 0.3%- Benzoyl Peroxide 2.5% Gel
Weiss et al. J Drugs in Dermatol 2015.
Melinda Gooderham
13:10-13:25 Interactive discussion Chaired by Jerry Tan
13:25-13:50 Article 2
Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy
Henry et al. CMAJ 2016.
Anick Bérard
13:50-14:05 Interactive discussion Chaired by Jerry Tan
14:05-15:15 Closing remarks, Evaluation Jerry Tan

 

Learning Objectives

At the end of the program, participants will be able to:

  1. Assess and critique clinical trial and administrative data for patients with severe inflammatory acne
  2. Discuss how study design, methodology, outcomes and limitations of a study influence change in the management of severe acne
  3. Outline appropriate patient selection for particular treatment strategies for patients with severe acne in light of clinical data

 

Saturday, June 24, 2017

08:30-10:00
Breakfast Symposium

Co-developed by AbbVie and the CDA

Chair: Kim A. Papp

The Clock is Ticking: The Risks of Waiting

Many specialties treat patients where the goal is to decrease systemic inflammation. Frequently, the window of intervention is time sensitive for optimal patient outcomes. Through this symposium, participants will explore the data that supports the strategy that early identification and diagnosis, followed by early initiation of an optimal treatment improves the success of achieving better patient outcomes. Additional data will be presented from the perspective of other specialities (rheumatology, cardiology and surgery) that also treat dermatology patients.

Speakers

  • Kim A. Papp, Dermatologist, MD, PhD, FRCPC, FAAD, K Papp Clinical Research and Probity Medical Research (Chair)
  • Sean Connors, MD, FRCPC, Associate Professor of Medicine (Cardiology), Memorial University, St. John’s, NL
  • Ralph George, General Surgeon, MD, FRSC, Medical Director, CIBC Breast Centre, St. Michael’s, Toronto, ON, Associate Professor, University of Toronto, Toronto, ON
  • Proton Rahman, Rheumatologist, MD, FRCPC, Associate Dean, Faculty of Medicine, Clinical Scientist and Professor of Medicine, Memorial University of Newfoundland, St. John’s, NL

Learning Objectives

At the end of the program, participants will: Recognize and translate into practice the benefits of treating early and optimally to decrease systemic inflammation,

  • In psoriasis to improve the quality of life and decrease the risk of co-morbidities
  • In psoriatic arthritis to inhibit further structural damage
  • In hidradenitis suppurativa to prevent progression, irreversible cutaneous damage and psychosocial impact.

 

12:40-14:10
Luncheon Symposium

Co-developed by Sanofi Genzyme and the CDA

Chair: Melinda Gooderham

Evolving Perspectives in Atopic Dermatitis: Do We Need New Treatment Options?

The management of moderate-to-severe atopic dermatitis (AD) in adults who fail to respond to topical therapies and phototherapy remains a clinical challenge for dermatologists, and a frustration for patients living with this disease. Currently, systemic immunosuppressive therapies that broadly target the immune system are used off-label in Canada for difficult-to-treat AD. In recent years, exciting advances in our understanding of the immunopathogenesis of AD have uncovered new targets for treatment. Several targeted therapies are now in clinical development and one is already approved by the FDA, with Phase 2 and Phase 3 studies demonstrating a new level of efficacy in adults with moderate-to-severe AD. These targeted therapies are poised to address the substantial unmet needs and burden of disease in patients living with moderate-to-severe AD.

Agenda

12:40-12:45 Introduction, overview & objectives Melinda Gooderham
12:45-12:55 New data on the burden of moderate-to-severe AD in adults: results of a recent survey by the Eczema Society of Canada Amanda Cresswell-Melville
12:55-13:15 Evolving concepts in the immunopathogenesis and clinical burden of atopic dermatitis Melinda Gooderham
13:15-13:30 The current landscape of managing adults with moderate-to-severe AD: Are we doing enough for our patients? Ron Vender
13:30-13:45 A look to the future: Evidence for emerging targeted treatments for moderate-to-severe AD in adults Yves Poulin
13:45-13:50 Summary & chair perspectives Melinda Gooderham
13:50-14:10 Panel discussion/questions & answers Melinda Gooderham

 

Learning Objectives

At the end of the program, participants will be able to:

  1. Explore the burden of atopic dermatitis including new Canadian data from the perspective of adult patients with moderate-to-severe disease
  2. Discuss advances in the understanding of the immunopathogenesis of atopic dermatitis
  3. Review the current challenges and opportunities in the management of adults with moderate-to-severe atopic dermatitis
  4. Examine the pros and cons of existing treatments and new targeted agents that are in development for the treatment of atopic dermatitis